Ziccum
0.94
SEK
+3.87 %
ZICC
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
+3.83%
-54.63%
-78.79%
-82.25%
-86.32%
-85.32%
-91.21%
-92.06%
-82.24%
ziccum.com/investors
Ziccum is a Swedish pharmaceutical company that develops new preparations of biological medicines. With the company's patented LaminarPace technology, dry preparation forms are developed for products that are currently available in liquid form. Most of the business is found around the Nordic region, and in addition to the main business, the company offers various related products. The company's head office is in Lund.
Revenue
3.75M
EBIT %
-574.93 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
ZICC
Daily low / high price
0.94 / 1.005
SEK
Market cap
48M SEK
Turnover
35.24K SEK
Volume
37K
Financial calendar
Annual report
2025-01-29
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Global Corporate Finance (GCF) | 7.2 % | 7.2 % |
| Avanza Pension | 6.6 % | 6.6 % |
| William Lithander | 5.9 % | 5.9 % |
| Göran Conradson | 4.8 % | 4.8 % |
| Tigerstaden AS | 2.6 % | 2.6 % |
| Nordnet Pensionsförsäkring | 2.3 % | 2.3 % |
| Kenneth Hopp | 1.7 % | 1.7 % |
| Per Gerde | 1.5 % | 1.5 % |
ShowingAll content types
Ziccum offentliggör prospekt med anledning av förestående företrädesemission
The board of directors of Ziccum has resolved on a previously announced rights issue of units of approximately SEK 30 million
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools